PhaseV, a leader in AI/ML-driven clinical development, announced the completion of a $50 million Series A funding round. This funding aims to support pharma, biotech, and CROs in leveraging AI to improve clinical trial outcomes. With this round, the company's total funding reaches $65 million. The investment will aid in expanding PhaseV's vertical AI solutions for clinical development.
Who to call at PhaseV, and when
A new round usually means PhaseV is about to hire and buy. The teams that reach out first get the meeting.
An alert the day PhaseV raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at PhaseV, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at PhaseV. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
PhaseV
Location
Boston, Massachusetts, United States
About
PhaseV is leveraging cutting-edge algorithms such as reinforcement learning and causal ML for adaptive trial design and closed-loop execution, in order to improve trial success rate while maximizing resource and time efficiency. Our novel methodology and advanced technology also enable the detection of hidden signals in data while analyzing clinical trial results and extracting actionable insights.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment PhaseV raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.